================================================================================
Chapter 7: Regulation and Approval
================================================================================
[Table of Contents]
Regulatory approval ensures safety and effectiveness. Pathways vary by
jurisdiction and device risk classification.
--------------------------------------------------------------------------------
7.1 FDA Approval Process (United States)
--------------------------------------------------------------------------------
Device Classification:
Class I: Low risk, general controls (mostly 510(k) exempt)
Class II: Moderate risk, general + special controls → 510(k) pathway
Class III: High risk, premarket approval (PMA) → most rigorous
510(k) Premarket Notification:
- Requirement: Demonstrate substantial equivalence to predicate device
- Contents: Device description, predicate comparison, performance testing,
biocompatibility (ISO 10993), software documentation, labeling
- Clinical: Generally not required if equivalence established
- Timeline: 90 days FDA goal (actual 4-12 months)
- Smart pill example: New pH sensor capsule vs. SmartPill predicate
De Novo Pathway:
- Scenario: No predicate exists but Class II appropriate
- Process: 510(k) → NSE (Not Substantially Equivalent) → De Novo request →
FDA reclassifies to Class II → approval (becomes future predicate)
- Example: Proteus sensor (first ingestible adherence sensor)
- Timeline: 150 days FDA goal
PMA (Premarket Approval):
- Standard: "Reasonable assurance" of safety and effectiveness
- Evidence: Scientific data (primarily clinical trials)
- Contents: Comprehensive summary, device description, manufacturing/QC,
nonclinical testing, clinical trials (pivotal), benefit-risk analysis, labeling
- Clinical: Usually mandatory (prospective, controlled, adequate sample size)
- Review: 180 days goal (actual 1-3 years), FDA multidisciplinary team,
advisory panel (for novel/controversial)
- Example: PillCam capsule endoscopy (2001 EU, 2007 US FDA)
Post-Approval:
- Conditions: Approved labeling only, approved manufacturing
- Surveillance: MDR (Medical Device Reporting) for adverse events
- Changes: PMA supplement or 30-day notice
- Inspections: Periodic manufacturing facility audits
--------------------------------------------------------------------------------
7.2 Clinical Trial Requirements
--------------------------------------------------------------------------------
IDE (Investigational Device Exemption):
- Purpose: Permit unapproved device use in clinical investigation
- NSR (Non-Significant Risk): IRB only (FDA exempted)
- SR (Significant Risk): IRB + FDA IDE approval
- Application: Protocol, risk analysis, device description, preclinical data,
investigator qualifications, informed consent, monitoring plan
- Review: 30 days (silence = approval), clinical hold, or disapproval
Trial Design:
Phase I analog: Initial safety/feasibility (10-30 subjects, open-label)
Phase II analog: Pilot efficacy (50-100 subjects, single-arm or small randomized)
Phase III analog: Pivotal efficacy (100-500+ subjects, randomized, controlled,
multicenter) - basis for PMA approval
Phase IV analog: Post-market (hundreds-thousands, real-world performance)
Endpoints:
- Primary: Pre-specified main efficacy measure (single, objective, clinically meaningful)
- Secondary: Additional benefits, safety
- Safety: AEs (adverse events), SAEs (serious: death, life-threatening, hospitalization,
permanent impairment), device-specific (obstruction, perforation, allergy)
Statistical Considerations:
- Sample size: Based on effect size, α = 0.05, power = 0.80-0.90, dropout
- Populations: ITT (intention-to-treat), PP (per-protocol), safety
- Hypothesis: Superiority, non-inferiority, or equivalence
- Interim analysis: DMB (Data Monitoring Board), alpha-spending methods
Patient Population:
- Inclusion: Diagnosis confirmed, appropriate age, informed consent
- Exclusion: Contraindications (strictures, pregnancy), severe comorbidities
- Informed consent: Purpose, procedures, risks/benefits, alternatives, confidentiality
--------------------------------------------------------------------------------
7.3 International Regulatory Standards
--------------------------------------------------------------------------------
European Union (MDR 2017/745):
- Classification: Annex VIII rules → typically Class IIa or IIb
- Conformity assessment: Notified Body (NB) review, technical documentation,
clinical evaluation (MEDDEV 2.7/1), quality system audit
- CE marking: Indicates EU compliance, valid 5 years
- Clinical investigation: ISO 14155, Competent Authority + Ethics Committee (60 days)
- PMCF (Post-Market Clinical Follow-up): Mandatory for all devices, updates CER
- UDI: Unique Device Identification in EUDAMED database
Japan (PMDA):
- Classification: Class I-IV (most smart pills Class II-III)
- Approval: PMDA review (6-12 months) → MHLW (Ministry) final approval
- Clinical: Generally required (Class III/IV), Japanese data preferred (bridging possible)
- Sakigake: Fast-track designation for breakthrough devices (6-month review)
- Post-approval: PMS (post-market surveillance), re-examination (3-7 years)
China (NMPA):
- Classification: Class I-III (most smart pills Class III)
- Approval pathway: CIR registration → clinical trial approval → trial (China) →
technical review (CMDE) → administrative review → NMPA approval (2-5 years)
- Clinical: Class III mandatory, Chinese subjects required
- Innovation: Special review for breakthrough devices (priority/expedited)
Other Markets:
- Canada (Health Canada): Class I-IV, Medical Device License (MDL)
- Australia (TGA): ARTG registration, EU CE recognition (mutual)
- Korea (MFDS): Grade 1-4, clinical data (Korean) for 3-4
- Brazil (ANVISA), India (CDSCO): Various national pathways
Harmonization:
- IMDRF (International Medical Device Regulators Forum): Risk classification,
clinical evaluation, UDI, cybersecurity guidance
- ISO 13485: Quality management system (global recognition)
- MDSAP (Medical Device Single Audit Program): Single audit for multiple countries
--------------------------------------------------------------------------------
7.4 Post-Market Surveillance
--------------------------------------------------------------------------------
Adverse Event Reporting:
US MDR (21 CFR 803):
- Manufacturers: Death (30d + 5d), serious injury (30d), malfunction (30d), baseline annual
- User facilities: Death (FDA + manufacturer, 10d), serious (manufacturer, 10d)
- Submission: eSTAR system
EU Vigilance (MDR Article 87-92):
- Serious incidents: Report to Competent Authority (2-10 days based on severity)
- FSCA (Field Safety Corrective Action): Recalls, field corrections, warnings
- EUDAMED database (future public access)
Post-Market Studies:
US Section 522: FDA-mandated PMA condition (long-term safety/efficacy, rare AEs,
specific subgroups, real-world performance)
EU PMCF: Plan (rationale, methods, data sources), active (studies) or passive
(literature, vigilance), updates CER
Registries:
- Purpose: Real-world evidence, long-term outcomes, comparative effectiveness
- Examples: Device-specific (e.g., PillCam registry), disease-specific (IBD registry),
national (MAUDE-US, EUDAMED-EU, J-MDRS-Japan)
Manufacturing Quality:
QSR (21 CFR 820 - US): Design controls, purchasing, production validation, inspection,
CAPA (corrective/preventive action), records
ISO 13485: International QMS standard, third-party certification
GMP: EU, China, other regions (similar to QSR/ISO 13485)
Inspections: Routine (2-4 years), for-cause (complaints, recalls), FDA 483 observations
Key Principle: Regulatory requirements evolve continuously. Stay updated with
latest guidance and collaborate with regulatory experts.
[Next: Chapter 8]
[Table of Contents]
================================================================================